Analysts’ Recent Ratings Updates for Revance Therapeutics (RVNC)

A number of research firms have changed their ratings and price targets for Revance Therapeutics (NASDAQ: RVNC):

• 12/28/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/23/2024 – Revance Therapeutics had its price target lowered by analysts at Barclays PLC from $7.00 to $3.00. They now have an “equal weight” rating on the stock.
• 12/20/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/12/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/10/2024 – Revance Therapeutics had its price target lowered by analysts at Mizuho from $6.66 to $3.10. They now have a “neutral” rating on the stock.
• 12/4/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/26/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/18/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/10/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/8/2024 – Revance Therapeutics had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $6.60 price target on the stock.
• 11/8/2024 – Revance Therapeutics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 11/2/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Revance Therapeutics Price Performance

NASDAQ:RVNC traded down $0.02 during mid-day trading on Wednesday, hitting $3.04. 1,380,855 shares of the company’s stock were exchanged, compared to its average volume of 2,777,570. The business has a fifty day moving average price of $4.04 and a 200 day moving average price of $4.50. Revance Therapeutics, Inc. has a one year low of $2.30 and a one year high of $9.74. The company has a market cap of $317.35 million, a PE ratio of -1.58 and a beta of 0.81.

Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. On average, equities analysts forecast that Revance Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Revance Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Alpine Associates Management Inc. bought a new position in shares of Revance Therapeutics during the 3rd quarter valued at about $21,605,000. LMR Partners LLP purchased a new position in Revance Therapeutics during the 3rd quarter valued at approximately $11,648,000. Stonepine Capital Management LLC increased its stake in Revance Therapeutics by 41.7% in the 2nd quarter. Stonepine Capital Management LLC now owns 2,800,000 shares of the biopharmaceutical company’s stock worth $7,196,000 after acquiring an additional 823,658 shares during the last quarter. Oddo BHF Asset Management Sas purchased a new stake in shares of Revance Therapeutics during the 3rd quarter worth approximately $3,763,000. Finally, Federated Hermes Inc. raised its holdings in shares of Revance Therapeutics by 43.0% during the 2nd quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock worth $5,750,000 after acquiring an additional 672,803 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.